drugset
drugset / Trial / NCT03494634

Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors

NCT03494634 ↗

Phase 2 Unknown 66 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

Study of Chidamide as a Single-agent Treatment for Patients With Recurrent and Metastatic Epstein-Barr virus (EBV)-associated Solid Tumors

Timeline

Start
2018-04-15
Primary completion
2019-09-30
Completion
2020-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tucidinostat Small molecule 30 mg Oral

Indications

Ehrlich tumor carcinoma